Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

• Daruka Mahadevan ,

  * E-mail: dmahadevan@westclinic.com (DM); wqi@uthsc.edu (WQ)

  Affiliation Department of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

  ⨯
• Carla Morales,

  Affiliation Department of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

  ⨯
• Laurence S. Cooke,

  Affiliation Department of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

  ⨯
• Ann Manziello,

  Affiliation Department of Medicine, The University of Arizona Cancer Center, Tucson, Arizona, United States of America

  ⨯
• David W. Mount,

  Affiliation Department of Medicine, The University of Arizona Cancer Center, Tucson, Arizona, United States of America

  ⨯
• Daniel O. Persky,

  Affiliation Department of Medicine, The University of Arizona Cancer Center, Tucson, Arizona, United States of America

  ⨯
• Richard I. Fisher,

  Affiliation Department of Medicine, Fox Chase Cancer Center – Temple Health, Philadelphia, Pennsylvania, United States of America

  ⨯
• Thomas P. Miller,

  Affiliation Department of Medicine, The University of Arizona Cancer Center, Tucson, Arizona, United States of America

  ⨯
• Wenqing Qi

  * E-mail: dmahadevan@westclinic.com (DM); wqi@uthsc.edu (WQ)

  Affiliation Department of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

  ⨯